Moderna's trading volume on February 17th was $451 million, a decrease of 35.66% compared to the previous trading day.

2026-02-20 08:04:29

Abstract generation in progress

On February 17, 2026, biotechnology company Moderna (MRNA) had a trading volume of $451 million, ranking 290th among U.S. stocks for the day. The trading volume decreased by 35.66% compared to yesterday, with a daily trading volume of 10.4188 million shares.

Moderna (MRNA) rose 4.03% on February 17, 2026, to $43.93. The stock has increased by 4.61% over the past five trading days, declined by 0.32% for the entire month of February, and has gained 48.97% since the beginning of the year. Over the past 52 weeks, it has increased by 33.16%.

*If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to companies listed for less than 1 month or fewer than 5 trading days).

Moderna (MRNA)	Trading Volume / USD	Change in Trading Volume from Yesterday	Shares Traded
February 17, 2026	$451 million	-35.66%	10.4188 million
February 13, 2026	$701 million	123.53%	16.3366 million
February 12, 2026	$314 million	-45.47%	7.9047 million
February 11, 2026	$575 million	33.09%	14.8817 million
February 10, 2026	$432 million	41.17%	9.9878 million

On February 17, 2026, Evercore ISI Group maintained a “Market Perform” rating for Moderna, with a target price of $35.

Moderna, Inc. was incorporated on July 22, 2016, under Delaware law. The company is a leader in messenger RNA (mRNA) medicine. With over a decade of work at the intersection of science, technology, and health, the company has developed drugs at an unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Its mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions. Driven by a unique culture and a global team guided by Moderna’s values and mindset, the company aims to responsibly change the future of human health by delivering the maximum possible impact through mRNA medicines.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes